Willemijn S.M.E. Theelen

Osimertinib or Platinum–Pemetrexed in <i>EGFR</i> T790M–Positive Lung Cancer

Tony Mok, Yi‐Long Wu, Myung‐Ju Ahn et al. · New England Journal of Medicine · 2016 · 3.2K citations · Full text

Effect of Pembrolizumab After Stereotactic Body Radiotherapy vs Pembrolizumab Alone on Tumor Response in Patients With Advanced Non–Small Cell Lung Cancer

Willemijn S.M.E. Theelen, Heike Peulen, Ferry Lalezari et al. · JAMA Oncology · 2019 · 935 citations · Full text

Pembrolizumab with or without radiotherapy for metastatic non-small-cell lung cancer: a pooled analysis of two randomised trials

Willemijn S.M.E. Theelen, Dawei Chen, Vivek Verma et al. · The Lancet Respiratory Medicine · 2020 · 540 citations

Medicine, Randomised Trials, Immune Checkpoint Inhibitor +6

Osimertinib or platinum–pemetrexed in EGFR T790M–positive lung cancer

Tony Mok, Yi‐Long Wu, M. Ahn et al. · QUT ePrints (Queensland University of Technology) · 2017 · 474 citations · Full text

Osimertinib versus platinum–pemetrexed for patients with EGFR T790M advanced NSCLC and progression on a prior EGFR-tyrosine kinase inhibitor: AURA3 overall survival analysis

Vassiliki A. Papadimitrakopoulou, Tony Mok, Ji‐Youn Han et al. · Annals of Oncology · 2020 · 266 citations · Full text